SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
ResMed Inc. (RMD) trades at a trailing P/E of 22.4, forward P/E of 20.9. Trailing earnings yield is 4.46%, forward earnings yield 4.79%. PEG 0.60 (Peter Lynch undervalued ≤1.0). Graham Number is $99.25.
Criteria proven by this page:
- VALUE (48/100, Partial) — mixed signals — some valuation metrics are favorable while others are stretched.
- Forward P/E 20.9 (down from trailing 22.4) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 0.60 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 4.46% — roughly competitive with bond yields (~4.3%), moderate risk-reward. Forward yield improves to 4.79% as earnings recover.
- Analyst consensus target $295.88 (+28.3% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 78/100 with 5/7 criteria passed.
SharesGrow 7-Criteria Score
~
VALUE
48/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — RMD
Valuation Multiples
P/E (TTM)22.4
Forward P/E20.9
PEG Ratio0.60
Forward PEG1.29
P/B Ratio5.26
P/S Ratio6.14
EV/EBITDA15.8
Per Share Data
EPS (TTM)$10.14
Forward EPS (Est.)$11.05
Book Value / Share$43.15
Revenue / Share$36.85
FCF / Share$12.21
Yields & Fair Value
Earnings Yield4.46%
Forward Earnings Yield4.79%
Dividend Yield1.03%
Graham Number$99.25
SharesGrow IV$344.37 (+49.3%)
Analyst Target$295.88 (+28.3%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2016 |
25.2 |
0.00 |
5.23 |
4.82 |
1.90% |
| 2017 |
32.2 |
-8.97 |
5.62 |
5.33 |
1.69% |
| 2018 |
46.9 |
-5.40 |
7.18 |
6.32 |
1.35% |
| 2019 |
43.8 |
1.56 |
8.55 |
6.79 |
1.20% |
| 2020 |
44.6 |
0.85 |
11.10 |
9.37 |
0.81% |
| 2021 |
75.5 |
-3.13 |
12.41 |
11.21 |
0.63% |
| 2022 |
39.3 |
0.62 |
9.11 |
8.56 |
0.80% |
| 2023 |
35.7 |
2.45 |
7.76 |
7.59 |
0.81% |
| 2024 |
26.9 |
2.01 |
5.65 |
5.87 |
1.03% |
| 2025 |
27.0 |
0.72 |
6.34 |
7.36 |
0.82% |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$2.49 |
$1.84B |
$352.41M |
19.2% |
| 2017 |
$2.40 |
$2.07B |
$342.28M |
16.6% |
| 2018 |
$2.19 |
$2.34B |
$315.59M |
13.5% |
| 2019 |
$2.80 |
$2.61B |
$404.59M |
15.5% |
| 2020 |
$4.27 |
$2.96B |
$621.67M |
21% |
| 2021 |
$3.24 |
$3.2B |
$474.51M |
14.8% |
| 2022 |
$5.30 |
$3.58B |
$779.44M |
21.8% |
| 2023 |
$6.09 |
$4.22B |
$897.56M |
21.3% |
| 2024 |
$6.92 |
$4.69B |
$1.02B |
21.8% |
| 2025 |
$9.51 |
$5.15B |
$1.4B |
27.2% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$11.05 |
$10.69 – $11.28 |
$5.64B |
$5.57B – $5.68B |
13 |
| 2027 |
$12.27 |
$11.47 – $12.61 |
$6.07B |
$5.97B – $6.12B |
13 |
| 2028 |
$13.43 |
$12.12 – $14.29 |
$6.48B |
$6.48B – $6.49B |
9 |
| 2029 |
$14.38 |
$14.13 – $14.59 |
$6.97B |
$6.88B – $7.05B |
3 |
| 2030 |
$16.20 |
$15.91 – $16.44 |
$7.79B |
$7.68B – $7.88B |
4 |
